BrainStorm Touts Biomarker Data for ALS Candidate After Two FDA Rebuffs | BioSpace
After its Biologics License Application was rejected by the FDA, BrainStorm’s Phase III data suggest its amyotrophic lateral sclerosis candidate significantly lowers neurofilament light chain levels.